NCT04868357Completed
Hypnosis for the Management of Anxiety and Breathlessness During a Pulmonary Rehabilitation Program
Efficacy of Self-administered Hypnosis for the Complementary Management of Anxiety and Dyspnea During Pulmonary Rehabilitation: A 2-armed Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 5 Jan 2026
Brief summary (registry, in English)
Patients with chronic obstructive pulmonary disease (COPD) are prone to breathlessness, chest tightness and other anxiety-inducing symptoms. Medical therapy for the condition focus on improving these symptoms and preventing exacerbations. However, as the disease progresses, pharmacological therapies become less and less effective. Patients with advanced COPD often feel less benefit from the treatment in terms of relief from their symptoms and relief from anxiety about their breathing. Hypnosis is known to induce immediate changes in how a person thinks and experiences their body. These changes can break vicious cycles of anxiety. Hypnosis has already been used successfully people with breathing problems to reduce anxiety and improve breathing. This trial aims to investigate the effect of hypnosis as a complementary technique for the self-management of breathlessness and anxiety during a Pulmonary Rehabilitation Program (PRP). As a secondary measure, the investigators aim to uncover whether the use of self-hypnosis remains useful during the three months following the PRP, after discharge from hospital.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 133 (actual)
- First submitted
- 23 Apr 2021
- Start date
- 27 Sept 2021
- Primary completion date
- 19 Apr 2024
- Lead sponsor
- Centre Hospitalier de Bligny
- Diseases
- COPD
- NCT number
- NCT04868357
What you commit to
- Study type: Interventional
- Participants enrolled: 133
- From 27 Sept 2021 to the primary completion date, 19 Apr 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known severe cardiac insufficiency.
- Known severe pulmonary arterial hypertension.
- Evolutive-cancer diagnosis.
- Significant cognitive impairment, hypercapnic encephalopathy or confusional syndrome.
Other
- Pregnancy
- Deafness.
- Anemia ≤ 8g/dL.
- Psychotic pathology.
Who the study is looking for
- Aged \> 30.
- Affiliated to a Social Security scheme or beneficiary of such a scheme.
- Absence of cognitive disease questioning the validity of patient reported outcomes
- Ability to give free, informed consent.
- Adult patients with severe COPD, dyspnea ; with distension.
- Hospitalized at the CHB.
- Predicted FEV1 and FEV/FVC percentages consistent with severe COPD according to GOLD standards.
- Modified Research Council Questionnaire ≥2
- Exposure to tobbacco \>= 10 packs/yrs.
Age in the registry: 30 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre hospitalier de Bligny Coordinator of this site? Confirm its status | Briis-sous-Forges | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.